PCI Biotech Holding ASA (OSL:PCIB) Ending Cash Position: kr13.62 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:PCIB PCI Biotech Holding ASA OSL:PCIB
6 GF Score
Price kr0.12
! 1 Warning Sign
View Full Analysis

What is PCI Biotech Holding ASA Ending Cash Position?

PCI Biotech Holding ASA OSL:PCIB -12.21% 6 Ending Cash Position is kr13.62 Mil as of Jun. 2025. GuruFocus rates OSL:PCIB with a GF Score™ of 6/100. The stock has 1 warning sign investors should review.

PCI Biotech Holding ASA's Ending Cash Position for the quarter that ended in Jun. 2025 was kr13.62 Mil.

PCI Biotech Holding ASA's quarterly Ending Cash Position declined from Jun. 2024 (kr30.54 Mil) to Dec. 2024 (kr27.07 Mil) and declined from Dec. 2024 (kr27.07 Mil) to Jun. 2025 (kr13.62 Mil).

PCI Biotech Holding ASA's annual Ending Cash Position declined from Dec. 2022 (kr56.60 Mil) to Dec. 2023 (kr41.18 Mil) and declined from Dec. 2023 (kr41.18 Mil) to Dec. 2024 (kr27.07 Mil).

PCI Biotech Holding ASA Ending Cash Position Related Terms

PCI Biotech Holding ASA Ending Cash Position Historical Data

* Premium members only.

The historical data trend for PCI Biotech Holding ASA's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PCI Biotech Holding ASA Ending Cash Position Chart

PCI Biotech Holding ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 187.97 116.12 56.60 41.18 27.07

PCI Biotech Holding ASA Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.58 41.18 30.54 27.07 13.62
OSL:PCIB
6GF Score
PCI Biotech Holding ASA OSL:PCIB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PCI Biotech Holding ASA Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

PCI Biotech Holding ASA's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=41.184+-14.115
=27.07

PCI Biotech Holding ASA's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=27.07+-13.453
=13.62

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of kr13.62 Mil mean?
PCI Biotech Holding ASA (OSL:PCIB) has a Ending Cash Position of kr13.62 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's Ending Cash Position too high?
PCI Biotech Holding ASA's current Ending Cash Position is kr13.62 Mil. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's Ending Cash Position compare to VRTX and REGN?
PCI Biotech Holding ASA's Ending Cash Position of kr13.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on PCI Biotech Holding ASA and its competitors. PCI Biotech Holding ASA's current Ending Cash Position is kr13.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current Ending Cash Position of kr13.62 Mil. The current Ending Cash Position is kr13.62 Mil. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current Ending Cash Position is kr13.62 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PCI Biotech Holding ASA Business Description

Address Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score

Get the complete analysis for OSL:PCIB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.12
Price